SAVARA INC.

Basic Information

900 S. Capital of Texas Hwy
Suite 150
Austin, TX, 78746

http://www.savarapharma.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 801937272
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 6


  1. Targeted nanoparticle gene therapy for lung cancer

    Amount: $190,353.00

    DESCRIPTION (provided by applicant): Project Summary A transformational NanoNucleic delivery technology is being investigated by Savara Inc. as a promising first-in-class gene therapy candidate for lu ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

    Amount: $3,986,098.00

    DESCRIPTION (provided by applicant): Persistent respiratory methicillin-resistant Staphylococcus aureus (MRSA) infections have become increasingly common in cystic fibrosis (CF) patients, with a prev ...

    SBIR Phase II 2013 Department of Health and Human Services
  3. Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

    Amount: $149,750.00

    DESCRIPTION (provided by applicant): Savara Inc. is developing a novel inhaled dry-powder form of vancomycin (AEROVANC) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infectio ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. A High Efficiency Corticosteroid Dry Powder Inhaler for Pediatric Use

    Amount: $184,148.00

    DESCRIPTION (provided by applicant): Asthma is a chronic respiratory disease with a global human and economic burden on patients, and society. Asthma treatment mainly consists of inhaled corticosteroi ...

    SBIR Phase I 2011 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government